title: Amantadine for olanzapine-induced weight gain: a systematic review and meta-analysis of randomized placebo-controlled trials.
abstract: OBJECTIVE
  The objective of this study was to conduct a systematic review and meta-analysis of randomized placebo-controlled trials of amantadine for the treatment of olanzapine-induced weight gain.
  
  
  METHODS
  Studies were identified using online searches of PUBMED/MEDLINE and Cochrane database (CENTRAL), along with websites recording trial information such as ClinicalTrials.gov, Controlled-trials.com, and Clinicalstudyresults.org. Study eligibility criteria included randomized, double-blind clinical trials comparing amantadine with placebo for olanzapine-induced weight gain with body weight as an outcome measure and study duration of at least 12 weeks. The methodological quality of included trials was assessed using the Jadad Scale. Separate meta-analyses were undertaken for each outcome (body weight and frequency of weight loss >7%) and treatment effects were expressed as weighted mean differences (WMD) and Mantel-Haenszel odds ratio for continuous and categorical outcomes, respectively.
  
  
  RESULTS
  A systematic review of literature revealed six studies that had assessed amantadine for olanzapine-induced weight gain. Of these, two studies (n = 144) met the review inclusion criteria and were included in the final analysis. Meta-analysis was performed to see the effect size of the treatment on body weight and frequency of body weight loss >7%. For body weight change, WMD was -1.85 (95% confidence interval [CI] -3.31 to -0.39) kg with amantadine as compared with placebo; the overall effect was statistically significant (p = 0.01). For frequency of body weight loss >7%, Mantel-Haenszel odds ratio for weight loss was 3.72 (95% CI 1.19-11.62), favoring amantadine as compared with placebo, and the overall effect was significant (p = 0.02).
  
  
  CONCLUSIONS
  Existing data is limited to two studies, which support the efficacy of amantadine for olanzapine-induced weight gain and a significant proportion of patients might lose weight with amantadine compared with placebo.
authors: Assistant Professor, Department of Psychiatry, Kasturba Medical College, Manipal, Karnataka 576104, India.
authors: Samir Kumar
authors: SK
authors: Praharaj
authors: Podila Satya Venkata Narasimha
authors: PS
authors: Sharma
keywords: amantadine; meta-analysis; olanzapine; systematic review; weight gain
references: N Engl J Med. 2005 Sep 22;353(12):1209-23
references: 16172203
references: J Clin Psychopharmacol. 2007 Dec;27(6):662-6
references: 18004133
references: CNS Drugs. 2008;22(6):477-95
references: 18484791
references: BMJ. 2001 Jul 7;323(7303):42-6
references: 11440947
references: BMC Psychiatry. 2009 Mar 28;9:12
references: 19327167
references: J Clin Psychiatry. 2001;62 Suppl 23:5-12
references: 11603886
references: Am J Psychiatry. 1999 Nov;156(11):1686-96
references: 10553730
references: Psychiatry Clin Neurosci. 2004 Apr;58(2):163-7
references: 15009821
references: J Clin Psychiatry. 1998 Sep;59(9):447-8
references: 9771813
references: J Clin Psychiatry. 1997;58 Suppl 10:45-9
references: 9265916
references: Schizophr Res. 2010 Aug;121(1-3):213-7
references: 20591628
references: Schizophr Bull. 2007 May;33(3):654-6
references: 17449900
references: J Clin Psychopharmacol. 1996 Dec;16(6):463-4
references: 8959477
references: BMJ. 2003 Sep 6;327(7414):557-60
references: 12958120
references: PLoS Med. 2009 Jul 21;6(7):e1000097
references: 19621072
references: Cochrane Database Syst Rev. 2006 Apr 19;(2):CD001169
references: 16625539
references: Neuropsychopharmacology. 2010 Jun;35(7):1520-30
references: 20336059
references: Can J Psychiatry. 2006 Jul;51(8):502-11
references: 16933587
references: Control Clin Trials. 1996 Feb;17(1):1-12
references: 8721797
references: Cochrane Database Syst Rev. 2010 Mar 17;(3):CD006654
references: 20238348
references: J Child Adolesc Psychopharmacol. 2002 Fall;12(3):249-57
references: 12427299
references: Eur Neuropsychopharmacol. 2005 Jan;15(1):13-21
references: 15572269
references: CNS Drugs. 2010 Mar;24(3):193-206
references: 20155995
references: Am J Psychiatry. 2005 Sep;162(9):1744-6
references: 16135638
references: Arch Gen Psychiatry. 2005 Jan;62(1):19-28
references: 15630069
references: Pharmacopsychiatry. 1997 Mar;30(2):43-54
references: 9131724
references: J Clin Psychiatry. 2009 Jul;70(7):1041-50
references: 19653979
references: Int Clin Psychopharmacol. 2007 Mar;22(2):69-76
references: 17293706
references: Eur Neuropsychopharmacol. 2001 Apr;11(2):181-2
references: 11313165